Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Sovaldi/Harvoni

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Sovaldi/Harvoni was produced by Gilead Sciences.

NHS England sees off AbbVie's Hep C legal challenge

NHS England sees off AbbVie's Hep C legal challenge

Maviret is in contention with rival treatments such as Gilead’s Sovaldi, Harvoni and Epclusa, to name a few.

Torrid times at Gilead lead to calls for a major M&A deal

Torrid times at Gilead lead to calls for a major M&A deal Sales of its hepatitis drugs Sovaldi, Harvoni and Epclusa were down $1.5bn in the same period of 2015 to $3.3bn, with overall revenues down almost 10% to $7.5bn

Gilead’s hepatitis C sales start to slide – the question is how quickly?

Gilead’s hepatitis C sales start to slide – the question is how quickly? The US pharma company has reaped the benefits of stellar sales for its directly-acting HCV therapies since it first launched Sovaldi (sofosbuvir) in 2013 and two-drug follow-up Harvoni

European pharma ‘to grow 3.2% per year by 2022’

European pharma ‘to grow 3.2% per year by 2022’ In hepatitis C, Gilead's Sovaldi (2015: 1.443 bn; 2022: 609m) and its follow-up therapy Harvoni (2015: 2 bn; 2022: 887m) million) will struggle due to price pressure and

FDA approves Gilead's 'universal' hep C combination Epclusa

FDA approves Gilead's 'universal' hep C combination Epclusa Epclusa joins Sovaldi and Harvoni (sofosbuvir/ledipasvir), a product specifically indicated for patients with hepatitis C virus genotype 1 infection, in Gilead's hep C portfolio. ... Sovaldi and Harvoni brought in sales of $5.3bn and $13.9bn respectively

1 2 3 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...